SUSAN ULERY: Open Payments
NPI 1184271637 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$390 in 15 payments from 8 companies in 2025. Trend: 2023 $464 · 2024 $79 · 2025 $390
Food & beverage: $390
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $116 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| ABBVIE INC. | 3 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $19 |
Products named: CAPLYTA, FANAPT, VRAYLAR, SPRAVATO, COBENFY, REXULTI, TRINTELLIX, Quviviq.
Industry payments across MA — which companies pay providers there.
